This is not the most recent version of the article. View current version (25 AUG 2017)

Intervention Protocol

You have free access to this content

Retinoic acid post consolidation therapy for high-risk neuroblastoma

  1. Frank Peinemann1,*,
  2. Carmen Bartel2,
  3. Ulrich Grouven3,
  4. Frank Berthold4

Editorial Group: Cochrane Childhood Cancer Group

Published Online: 31 JUL 2013

DOI: 10.1002/14651858.CD010685

How to Cite

Peinemann F, Bartel C, Grouven U, Berthold F. Retinoic acid post consolidation therapy for high-risk neuroblastoma (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD010685. DOI: 10.1002/14651858.CD010685.

Author Information

  1. 1

    Children's Hospital, University of Cologne, Cologne, NW, Germany

  2. 2

    Cologne, Germany

  3. 3

    Hannover Medical School, Hannover, Germany

  4. 4

    Children's Hospital, University of Cologne, Pediatric Oncology and Hematology, Cologne, Germany

*Frank Peinemann, Children's Hospital, University of Cologne, Kerpener Str. 62, Cologne, NW, 50937, Germany.

Publication History

  1. Publication Status: New
  2. Published Online: 31 JUL 2013


This is not the most recent version of the article. View current version (25 AUG 2017)


Additional references

Brisse 2011
  • Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261(1):243-57.
Brodeur 1993
  • Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology 1993;11(8):1466-77.
Cohn 2009
  • Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology 2009;27(2):289-97.
Cole 2012
  • Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clininical Cancer Research 2012;18(9):2423-8.
CTEP 2010
  • Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE). (accessed 08 July 2013).
DerSimonian 1986
EndNote 2012
  • Thomson Reuters. EndNote. X3. New York City: Thomson Reuters, 2012.
Esiashvili 2007
GARD 2011
  • Genetic and Rare Diseases Information Center (GARD), The Office of Rare Diseases Research (ORDR). Neuroblastoma. (accessed 08 July 2013).
Goodman 2012
  • Goodman MT, Gurney JG, Smith MA, Olshan AF. SEER Pediatric Monograph. Sympathetic Nervous System Tumors. (accessed 08 July 2013).
GRADEpro 2008
  • Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEprofiler (GRADEpro). Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
Grissom 1996
Hero 2008
  • Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. Journal of Clinical Oncology 2008;26(9):1504-10.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
ICSSC 2003
  • The International Clinical Sciences Support Center (ICSSC). WHO Toxicity Grading Scale for Determining The Severity of Adverse Events. (accessed 08 July 2013).
Kremer 2008
  • Kremer LCM, van Dalen EC, Moher D, Caron HN. Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). Available from 2008.
Matthay 1999
  • Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New England Journal of Medicine 1999;341(16):1165-73.
Matthay 2012
Moher 2009
NCI PDQ 2012
  • National Cancer Institute: PDQ® Neuroblastoma Treatment. Bethesda, MD: National Cancer Institute. Date last modified 16 November 2012. (accessed 08 July 2013).
Olson 1983
Parmar 1998
Review Manager 2013
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Reynolds 2003
Sidell 1982
  • Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. Journal of the National Cancer Institute 1982;68(4):589-96.
Sidell 1983
  • Sidell N, Altman A, Haussler MR, Seeger RC. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Experimental Cell Research 1983;148(1):21–30.
Tierney 2007
  • Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007 2007;8:16.
Turman 1999
Villablanca 1993
  • Villablanca JG, Khan AA, Avramis VI, Reynolds CP. Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid. American Journal of Pediatric Hematology Oncology 1993;15(4):410-5.
Villablanca 1995
  • Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. Journal of Clinical Oncology 1995;13(4):894-901.
Yalcin 2010